# A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

> **NCT05050942** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Camurus AB** · enrollment: 332 (actual)

## Conditions studied

- Gastro-enteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** CAM2029
- **DRUG:** Octreotide LAR
- **DRUG:** Lanreotide ATG

## Key facts

- **NCT ID:** NCT05050942
- **Lead sponsor:** Camurus AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-22
- **Primary completion:** 2026-07
- **Final completion:** 2028-07
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050942, "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05050942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*